Karen L. Reckamp, MD, discusses the Lung-MAP nonmatched substudy S1800A for patients with non–small cell lung cancer who were previously treated with immune checkpoint inhibitors and develop resistance.
Karen L. Reckamp, MD, a professor in Medicine, director of the Division of Medical Oncology at Cedars-Sinai Medical Center, and medical oncologist at the Samuel Oschin Cancer Center, discusses the Lung-MAP nonmatched substudy S1800A (NCT03971474) for patients with non–small cell lung cancer (NSCLC) who were previously treated with immune checkpoint inhibitors and develop resistance.
Results of the phase 2 trial were reported at the 2022 American Society of Clinical Oncology (ASCO) annual meeting by lead investigator Reckamp.
This phase 2 clinical trial is investigating the efficacy of the combination of ramucirumab (Cyramza) and pembrolizumab (Keytruda) vs standard of care in this patient population. The primary end point of the study is overall survival with secondary end points including progression-free survival, duration of response rates, and incidence of adverse events.
Overall data indicated that the combination of ramucirumab and pembrolizumab may extend the lives of those diagnosed with NSCLC.
0:08 | Lung-MAP is a precision medicine platform trial. It allows patients to have genomic testing through FoundationOne, and from that, go on to either a match trial if there's a genomic alteration, or down to the unmatched arm. This was the unmatched arm, S1800A. The combination of ramucirumab and pembrolizumab was for patients who did not meet criteria for the mast arms that we had available at that time.
0:35 | This was a randomized phase 2 trial and we wanted to see if there was an indication of efficacy. We knew that overall survival in general has been a better indication of efficacy, especially with immunotherapy in the second line setting. We chose to use overall survival as our primary endpoint. Knowing that we often do see discordance of overall survival with things like progression-free survival, we do often see discordance with overall survival and other outcomes such as progression-free survival and objective response.